The Biotech companies have shown tremendous growth in the Australian markets in the past decades or so. Many of the start-ups in this field are also witnessing phenomenal drive and performing well. Let us now have a close look at two of the hot biotech stocks listed on the bourses – BGT & TLX.
Bio-Gene Technology Ltd
Bio-Gene Technology Limited (ASX: BGT) operates as a biotechnology company. The Company develops insecticides that address the problems of insecticide resistance and toxicity. Bio-Gene Technology serves clients in Australia.
In a recent development, one of the directors of the company Mr. Donald Charles Brumley who held 1,000,000 ordinary shares in his direct capacity and 200,000 shares indirectly, acquired 150,000 shares for a consideration of $ 15,031.36 as on 1 March 2019. Hence after this development, Mr Brumley holds 1,000,000 ordinary shares in his direct capacity and 350,000 shares indirectly.
For the half year, which ended on ended 31 December 2018, the Company produced a loss from ordinary activities before income tax of $1.27 million, an 18.3% reduction over the previous corresponding period due primarily to the costs associated with the listing of the Company in November 2017. The Company’s cash position at the balance sheet date was $5.3 million. This mainly reflected the advancement of the research programs. Revenues generated for the current period of $78,210 were from interest income. Revenues of $45,534 for the corresponding period last year were interest income and sales of QcideTM.
BGT’ shares traded at $0.099, up by 7.609% during the day’s trade, with a market capitalisation of $ 11.87 Mn as of 22 March 2019. The stock generated a YTD return of -12.38% and -20.0% returns over the past three months.
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (ASX: TLX) operates as a biotechnology company. The Company develops and commercializes molecularly-targeted radiation therapy for the treatment of prostate, renal, and brain cancer. Telix Pharmaceuticals serves patients worldwide.
In a recent development, the European Association of Urology issued updated guidelines for Prostate Cancer Imaging. This imaging is now to include PSMA PET imaging in the management of “biochemical recurrence” patients. The EAU guidelines are a vital resource for establishing clinical practice standards for urologic oncology in Europe. The issuance of more extensive guidance around PSMA PET imaging significantly benefits Telix because it considerably de-risks the pathway for clinical adoption of our prostate imaging product.
Recently, Telix Pharmaceuticals Limited released full-year 2018 results. As per the release, the group is now a revenue-stage company, through the early commercialisation of the illumetTM product (prostate cancer imaging kit) and delivered first trade revenue of $195,142 in FY18. With the acquisition of Advanced Nuclear Medicine Ingredients SA (ANMI), the company is now able to develop and deliver a global strategy for prostate cancer imaging and expects to conclude commercially significant agreements with key marketing and distribution partners as 2019 progresses. It’s net loss increased by circa 116% to $13,829,825 as compared to the previous period. It was majorly impacted by higher operating expenses such as R&D costs, administrative & consulting costs, and Employment costs incurred during the same period. However, the company recorded an R&D tax incentive income of $10,141,969 in 2018 as compared to $403,467 in 2017. No dividend was recommended or paid during the year.
In its guidance, the company expects completion of enrolment of the TLX250-CDx trial by the end of Q4 FY2019. It has commenced sites work at Australia, Europe, and the US. It also plans to add sites at Canada and Turkey. It has partnered with GenesisCare in Australia for its Phase 2 portion of the TLX101 therapy program. It also expects to submit a New Drug Application to the US Food and Drug Administration for the prostate imaging product.
TLX’s shares traded at $0.655 with the market capitalisation of ~$ 143.03 Mn. The stock generated a YTD return of 0.77% and 27.18% returns over the past one year.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.